Enanta has discovered novel protease inhibitors and NS5A inhibitors that are members of the direct-acting-antiviral (DAA) inhibitor classes designed for use against the hepatitis C virus (HCV). moreEnantas protease inhibitors, developed through its collaboration with AbbVie, include paritaprevir, which is contained in AbbVies marketed DAA regimens for HCV, and ABT-493, Enantas second protease inhibitor, which AbbVie is developing in Phase 3 studies in combination with ABT-530, AbbVies NS5A inhibitor. Enanta has also discovered a cyclophilin inhibitor, EDP-494, a novel host-targeting mechanism for HCV, which is now in a clinical proof of concept study in HCV patients, and EDP-305, a non-bile acid FXR agonist for NASH, currently in Phase 1 clinical development. Please visit www.enanta.com for more information on our programs and pipeline. Read More Forward Looking Statements Disclaimer This press release contains forward-looking statements, including statements with respect to the prospects for clinical development of one of Enantas early lead compounds for the treatment of NASH. Statements that are not historical facts are based on managements current expectations, estimates, forecasts and projections about Enantas business and the industry in which it operates and managements beliefs and assumptions. The statements contained in this release are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Full ArticleImportant factors and risks that may affect actual results include: the development risks of early stage discovery efforts in disease areas such as NASH that have no current therapeutic treatment; potential competition from the development efforts of others in this disease area; Enantas lack of clinical development experience; Enantas need to attract and retain senior management and key scientific personnel; Enantas need to obtain and maintain patent protection for its product candidates and avoid potential infringement of the intellectual property rights of others; and other risk factors described or referred to in Risk Factors in Enantas most recent Form 10-K for the fiscal year ended September 30, 2015 and other periodic reports filed more recently with the Securities and Exchange Commission. Enanta cautions investors not to place undue reliance on the forward-looking statements contained in this release.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/enanta-pharmaceuticals-initiates-phase-1-201200159.html